Abstract: This invention relates to a detection system for measuring a fluorescent signal in a fluorescent assay. The system comprises a probe having a small sensing surface bound with a fluorescent label, and a light source and a detector both mounted at the proximal side of the sensing surface of the substrate. The invention also relates to a method for detecting an analyte in a liquid sample using a probe tip having a small surface area (?5 mm) and a high molecular weight polymer (?1 MD) having multiple binding molecules and multiple fluorescent labels. The binding reaction is accelerated by flowing the reaction solutions laterally and moving the probe tip up and down in the reaction vessels. The invention furthers relates to a fluorescent labeling composition comprising a cross-linked FICOLL® molecule having a plurality of binding molecules and a plurality of fluorescent labels.

Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The inventio further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.

Abstract: The present invention is directed to an assembly for use in detecting an analyte in a sample based on thin-film spectral interference. The assembly comprises a waveguide, a monolithic substrate optically coupled to the waveguide, and a thin-film layer directly bonded to the sensing side of the monolithic substrate. The refractive index of the monolithic substrate is higher than the refractive index of the transparent material of the thin-film layer. A spectral interference between the light reflected into the waveguide from a first reflecting surface and a second reflecting surface varies as analyte molecules in a sample bind to the analyte binding molecules coated on the thin-film layer.

Abstract: The present invention is directed to an assembly for use in detecting an analyte in a sample based on thin-film spectral interference. The assembly comprises a waveguide, a monolithic substrate optically coupled to the waveguide, and a thin-film layer directly bonded to the sensing side of the monolithic substrate. The refractive index of the monolithic substrate is higher than the refractive index of the transparent material of the thin-film layer. A spectral interference between the light reflected into the waveguide from a first reflecting surface and a second reflecting surface varies as analyte molecules in a sample bind to the analyte binding molecules coated on the thin-film layer.

Abstract: Disclosed are an Hsp90 inhibitor and a preparation method and use thereof. The Hsp90 inhibitor is 2-(4-(3-acetylcarnitineacyloxy)cyclohexylamino)-4-(1-(3,6,6-trimethyl-4-oxy-4,5,6,7-tetrahydroindazole))benzamide. The Hsp90 inhibitor has good water solubility and high bioavailability, and can effectively inhibit the proliferation of cancer cells, such as leukemia, cervical cancer, breast cancer, human laryngeal epithelial carcinoma, or malignant melanoma cells. It can also effectively inhibit the activity of herpes simplex virus. The maximal non-toxic concentration of the Hsp90 inhibitor on normal cells is a high, and the Hsp90 inhibitor only has specific inhibition effect on cancer cells.

Abstract: This invention relates to a detection system for measuring a fluorescent signal in a fluorescent assay. The system comprises a probe having a small sensing surface bound with a fluorescent label, and a light source and a detector both mounted at the proximal side of the sensing surface of the substrate. The invention also relates to a method for detecting an analyte in a liquid sample using a probe tip having a small surface area (?5 mm) and a high molecular weight polymer (?1 MD) having multiple binding molecules and multiple fluorescent labels. The binding reaction is accelerated by flowing the reaction solutions laterally and moving the probe tip up and down in the reaction vessels. The invention furthers relates to a fluorescent labeling composition comprising a cross-linked FICOLL® molecule having a plurality of binding molecules and a plurality of fluorescent labels.

Abstract: This invention relates to a detection system for measuring a fluorescent signal in a fluorescent assay. The system comprises a probe having a small sensing surface bound with a fluorescent label, and a light source and a detector both mounted at the proximal side of the sensing surface of the substrate. The invention also relates to a method for detecting an analyte in a liquid sample using a probe tip having a small surface area (?5 mm) and a high molecular weight polymer (?1 MD) having multiple binding molecules and multiple fluorescent labels. The binding reaction is accelerated by flowing the reaction solutions laterally and moving the probe tip up and down in the reaction vessels. The invention furthers relates to a fluorescent labeling composition comprising a cross-linked Ficoll molecule having a plurality of binding molecules and a plurality of fluorescent labels.

Abstract: This invention relates to a detection system for measuring a fluorescent signal in a fluorescent assay. The system comprises a probe having a small sensing surface bound with a fluorescent label, and a light source and a detector both mounted at the proximal side of the sensing surface of the substrate. The invention also relates to a method for detecting an analyte in a liquid sample using a probe tip having a small surface area (?5 mm) and a high molecular weight polymer (?1 MD) having multiple binding molecules and multiple fluorescent labels. The binding reaction is accelerated by flowing the reaction solutions laterally and moving the probe tip up and down in the reaction vessels. The invention furthers relates to a fluorescent labeling composition comprising a cross-linked Ficoll molecule having a plurality of binding molecules and a plurality of fluorescent labels.

Abstract: The present invention is directed to an assembly for use in detecting an analyte in a sample based on thin-film spectral interference. The assembly comprises a waveguide, a monolithic substrate optically coupled to the waveguide, and a thin-film layer directly bonded to the sensing side of the monolithic substrate. The refractive index of the monolithic substrate is higher than the refractive index of the transparent material of the thin-film layer. A spectral interference between the light reflected into the waveguide from a first reflecting surface and a second reflecting surface varies as analyte molecules in a sample bind to the analyte binding molecules coated on the thin-film layer.

Abstract: A S-VPN gateway provides a signaling gateway to integrate SIP signaling and UNI/NNI signaling, and manage the mapping between SIP sessions and VPN connections. The mapping relationship reflects the access of user applications to the specific VPN tunnels, multiplexing of media service sessions to VPN tunnels, VPN service creation, service duration, VPN QoS, VPN service life cycle management, and VPN service charge based on a per-service-usage. The S-VPN gateway also provides VPN access policy/security management (i.e., inter-domain AAA process), VPN membership auto-discovery, service auto-discovery, network resource auto-discovery, address resolution service for both SIP and VPN naming space, VPN service mobility, and SLA management. The S-VPN gateway enables network VPN tunnels to be created in advanced and accessed on-demand, for example by enterprise VPN applications such as GRID applications, through a SIP interface.

Abstract: A polysilicon silicide electric fuse device, comprising: a substrate; a semiconductor material layer disposed on said substrate, said semiconductor material layer includes lead-out areas of the same doping type at both ends, and an intermediate area of non-doping or having dopant concentration lower than those of said lead-out areas at both ends; and one or more burn-out areas is/are provided in said intermediate area; and a metal silicide layer is provided on said semiconductor material layer. Through the application of said polysilicon silicide electric fuse device, the burning out of said fuse device is thus controlled to within said intermediate area of no doping or light doping, hereby increasing the mean value and reducing distribution area of electrical resistance after burning out of a fuse, and alleviating the overheating of surrounding areas as caused by a current during the burning out of a fuse.

Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.

Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L, polypeptides.

Abstract: A peroxisome-associated polypeptide and a nucleotide sequence encoding the peroxisome-associated polypeptide are disclosed. The protein is useful in the diagnosis and/or treatment of several diseases, particularly lung injuries and diseases as well as oxidative stress-related disorders, particularly neurotoxic injury or exitotoxic injury.

Abstract: A S-VPN gateway provides a signaling gateway to integrate SIP signaling and UNI/NNI signaling, and manage the mapping between SIP sessions and VPN connections. The mapping relationship reflects the access of user applications to the specific VPN tunnels, multiplexing of media service sessions to VPN tunnels, VPN service creation, service duration, VPN QoS, VPN service life cycle management, and VPN service charge based on a per-service-usage. The S-VPN gateway also provides VPN access policy/security management (i.e., inter-domain AAA process), VPN membership auto-discovery, service auto-discovery, network resource auto-discovery, address resolution service for both SIP and VPN naming space, VPN service mobility, and SLA management. The S-VPN gateway enables network VPN tunnels to be created in advanced and accessed on-demand, for example by enterprise VPN applications such as GRID applications, through a SIP interface.

Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.

Abstract: The present invention provides novel Interleukin-1 Receptor Antagonist-Related (IL-1ra-R) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing IL-1ra-R polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with IL-1ra-R polypeptides.

Abstract: The present invention provides Fibroblast Growth Factor Receptor-Like (FGFR-L) polypeptides and nucleic acid molecules encoding the same. The invention also provides selective binding agents, vectors, host cells, and methods for producing FGFR-L polypeptides. The invention further provides pharmaceutical compositions and methods for the diagnosis, treatment, amelioration, and/or prevention of diseases, disorders, and conditions associated with FGFR-L polypeptides.